FDA Approves Johnson & Johnson’s Chemotherapy-Free Regimen for EGFR-Mutated Lung Cancer
Kiran Patel, Vice President of Clinical Development in Solid Tumor Franchise at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on LinkedIn:
“I am proud to announce the U.S. FDA approval of our chemotherapy-free combination regimen for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer. This approval follows the recent publication of our Phase 3 MARIPOSA data in NEJM Group as well as priority review by FDA and is the second new indication approval for this treatment this year.
Today’s approval is proof of how Johnson and Johnson Innovative Medicine is working to transform care for everyone affected by this disease.”
Peter Lebowitz, Global Oncology Therapeutic Area Head of SVP at Janssen, Pharmaceutical Companies of Johnson and Johnson, shared this post, adding:
“Congratulations to the Rybrevant team. This program is an amazing example of world class innovation in discovery and development driven by an extraordinary team.”
Source: Kiran Patel/LinkedIn and Peter Lebowitz/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023